HRP20030383B1 - Laktamski spoj - Google Patents

Laktamski spoj

Info

Publication number
HRP20030383B1
HRP20030383B1 HR20030383A HRP20030383A HRP20030383B1 HR P20030383 B1 HRP20030383 B1 HR P20030383B1 HR 20030383 A HR20030383 A HR 20030383A HR P20030383 A HRP20030383 A HR P20030383A HR P20030383 B1 HRP20030383 B1 HR P20030383B1
Authority
HR
Croatia
Prior art keywords
compound
lactamic
methyl
benzazepin
alanyl
Prior art date
Application number
HR20030383A
Other languages
English (en)
Croatian (hr)
Inventor
Edmund Audia James
Varghese John
H. Latimer Lee
Leigh Mcdaniel Stacey
Scott Nissen Jeffrey
D. Thorsett Eugene
S. Tung Jay
Original Assignee
Eli Lilly And Company
Elan Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company, Elan Pharmaceuticals filed Critical Eli Lilly And Company
Publication of HRP20030383A2 publication Critical patent/HRP20030383A2/xx
Publication of HRP20030383B1 publication Critical patent/HRP20030383B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
HR20030383A 2000-11-17 2001-11-05 Laktamski spoj HRP20030383B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24955200P 2000-11-17 2000-11-17
PCT/US2001/027799 WO2002047671A2 (en) 2000-11-17 2001-11-05 Lactam compound to inhibit beta-amyloid peptide release or synthesis

Publications (2)

Publication Number Publication Date
HRP20030383A2 HRP20030383A2 (en) 2005-10-31
HRP20030383B1 true HRP20030383B1 (hr) 2007-12-31

Family

ID=22943982

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030383A HRP20030383B1 (hr) 2000-11-17 2001-11-05 Laktamski spoj

Country Status (33)

Country Link
US (1) US20050261495A1 (https=)
EP (1) EP1341531B1 (https=)
JP (1) JP4116437B2 (https=)
KR (1) KR100819679B1 (https=)
CN (1) CN1486184A (https=)
AR (1) AR035927A1 (https=)
AU (2) AU4319202A (https=)
BR (1) BR0115427A (https=)
CA (1) CA2427227C (https=)
CY (1) CY1106366T1 (https=)
CZ (1) CZ20031351A3 (https=)
DE (1) DE60126132T2 (https=)
DK (1) DK1341531T3 (https=)
DZ (1) DZ3453A1 (https=)
EA (1) EA005954B1 (https=)
EC (1) ECSP034600A (https=)
ES (1) ES2278804T3 (https=)
HR (1) HRP20030383B1 (https=)
HU (1) HU228117B1 (https=)
IL (2) IL155960A0 (https=)
MX (1) MXPA03004292A (https=)
MY (1) MY134559A (https=)
NO (1) NO324324B1 (https=)
NZ (1) NZ525854A (https=)
PE (1) PE20020802A1 (https=)
PL (1) PL212199B1 (https=)
PT (1) PT1341531E (https=)
SI (1) SI1341531T1 (https=)
SK (1) SK288065B6 (https=)
TW (1) TWI305204B (https=)
UA (1) UA74849C2 (https=)
WO (1) WO2002047671A2 (https=)
ZA (1) ZA200303789B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US8114886B2 (en) 2005-04-08 2012-02-14 Daiichi Sankyo Company, Limited Pyridylmethylsulfone derivative
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
US8258302B2 (en) 2006-01-31 2012-09-04 Api Corporation Method for producing benzazepinone
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2193117A1 (en) * 2007-07-16 2010-06-09 Wyeth a Corporation of the State of Delaware Inhibitors of beta amyloid production
MX2010001754A (es) 2007-08-14 2010-05-14 Lilly Co Eli Derivados de azepina como inhibidores de gamma secretasa.
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
KR101595238B1 (ko) 2007-12-21 2016-02-18 리간드 파마슈티칼스 인코포레이티드 선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
CA2883896C (en) 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
JP6319912B2 (ja) 2013-04-19 2018-05-09 国立大学法人 岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
JP6840774B2 (ja) 2016-05-16 2021-03-10 ザ ジェネラル ホスピタル コーポレイション 肺上皮エンジニアリングにおけるヒト気道幹細胞
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019148067A1 (en) 2018-01-26 2019-08-01 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833669A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
AU2020257397B2 (en) 2019-04-19 2026-02-26 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
US12595248B2 (en) 2019-12-17 2026-04-07 Merck Sharp & Dohme Llc PRMT5 inhibitors
CN115003303B (zh) 2019-12-17 2024-03-08 默沙东公司 Prmt5抑制剂
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
JP7589247B2 (ja) 2019-12-17 2024-11-25 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｒｍｔ５阻害剤
JP2025511436A (ja) 2022-09-02 2025-04-16 メルク・シャープ・アンド・ドーム・エルエルシー エキサテカン由来トポイソメラーゼ－１阻害薬医薬組成物及びその使用
CN120417935A (zh) 2022-10-25 2025-08-01 默沙东有限责任公司 依喜替康衍生的adc接头-载荷及其药物组合物和用途
US20240207425A1 (en) 2022-12-14 2024-06-27 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002100B1 (ru) * 1996-12-23 2001-12-24 Элан Фармасьютикалз, Инк. ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ
WO1999067219A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
JP2003513958A (ja) * 1999-11-09 2003-04-15 イーライ・リリー・アンド・カンパニー β−アミロイドペプチド放出および／またはその合成を阻害するために有用なβ−アミノ酸化合物
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
CA2425558C (en) * 2000-11-17 2012-01-03 Eli Lilly And Company Lactam compound
UA77165C2 (en) * 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition

Also Published As

Publication number Publication date
EP1341531A2 (en) 2003-09-10
ES2278804T3 (es) 2007-08-16
DE60126132D1 (de) 2007-03-08
CA2427227C (en) 2010-08-17
AR035927A1 (es) 2004-07-28
AU2002243192B2 (en) 2006-07-20
DE60126132T2 (de) 2007-10-18
ECSP034600A (es) 2003-06-25
EP1341531B1 (en) 2007-01-17
HK1059731A1 (en) 2004-07-16
PL362688A1 (en) 2004-11-02
MXPA03004292A (es) 2004-02-12
WO2002047671A3 (en) 2003-03-06
HU228117B1 (en) 2012-11-28
IL155960A0 (en) 2003-12-23
HRP20030383A2 (en) 2005-10-31
TWI305204B (en) 2009-01-11
KR100819679B1 (ko) 2008-04-04
HUP0301842A2 (hu) 2003-09-29
DZ3453A1 (fr) 2002-06-20
BR0115427A (pt) 2003-10-07
NO20032236L (no) 2003-07-10
EA200300580A1 (ru) 2003-10-30
NO20032236D0 (no) 2003-05-16
ZA200303789B (en) 2004-08-16
CN1486184A (zh) 2004-03-31
CA2427227A1 (en) 2002-06-20
SI1341531T1 (sl) 2007-06-30
SK288065B6 (sk) 2013-04-03
PE20020802A1 (es) 2002-09-10
EA005954B1 (ru) 2005-08-25
IL155960A (en) 2009-06-15
KR20030051846A (ko) 2003-06-25
UA74849C2 (en) 2006-02-15
SK5592003A3 (en) 2003-12-02
AU4319202A (en) 2002-06-24
CY1106366T1 (el) 2011-10-12
MY134559A (en) 2007-12-31
JP4116437B2 (ja) 2008-07-09
JP2004517090A (ja) 2004-06-10
US20050261495A1 (en) 2005-11-24
PL212199B1 (pl) 2012-08-31
NZ525854A (en) 2004-06-25
WO2002047671A2 (en) 2002-06-20
CZ20031351A3 (cs) 2003-11-12
NO324324B1 (no) 2007-09-24
DK1341531T3 (da) 2007-05-14
HUP0301842A3 (en) 2010-03-29
PT1341531E (pt) 2007-04-30

Similar Documents

Publication Publication Date Title
HRP20030383B1 (hr) Laktamski spoj
ATE403429T1 (de) Spiropyrazol-verbindungen
EA200300050A1 (ru) Гликопептидфосфонатные производные
NO20041493L (no) Kjemiske forbindelser.
CY1109989T1 (el) 3,4-di-υποκαθισταμενες cyclobutene-1,2-diones ως συνδετες του υποδοχεα των cxc-χημειοκινων
EA199900373A2 (ru) Фармацевтические композиции
BR0116217A (pt) Quinolonas antimicrobianas, composição farmacêutica, bem como aplicação farmacêutica das referidas quinolonas
JO2654B1 (en) Multiple aryl caroxa amides are useful as lipid - lowering agents
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
SE0004245D0 (sv) Novel compounds and their use
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
MXPA03009602A (es) Analogos de nociceptina.
TR200002932T2 (tr) Azabisayklik 5HT1 Alıcı liganolları
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
BR9902084A (pt) Heterociclos.
TR199901017A2 (xx) B�cek ilac� terkibi.
ATE257139T1 (de) Ein (1'r,2's,5'r)-3-l-menthoxypropan-1-ol, das eine kühlende empfindung erzeugt
DK1204659T3 (da) Serotonerge benzofuraner
ATE280169T1 (de) Serotonerge benzothiophene
MXPA03011128A (es) Composicion de sabor y fragancia.
MXPA02011234A (es) Nuevas bases de oxidacion 2,5-diaminopiridina utiles para el tinte de las fibras queratinicas.
EA200400661A1 (ru) Фенилалкины
DK1144423T3 (da) Bis-terpyridin-platin(II)-komplekser
DE69915688D1 (de) Benzonaphtyridin-1,8 derivate
SE9901062D0 (sv) Use for conifer sapling protection

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20131029

Year of fee payment: 13

PBON Lapse due to non-payment of renewal fee

Effective date: 20141105